Cash from Zimmer certainly not received in half (hence why revenue grew so much yet little movement in cash). Likely for Convatec too.
Zimmer are reported to have bought only 2 months of product … if this forecast is correct, I would think Q3 revenue growth would likely be flat (but more cash) then growth again in Q4. If optimistic … revenue will dip. Revenue growth from direct channel needs to accelerate beyond US$100K/qrt. By my guestimates Xperience sales are <US$2,000 per surgeon per qrt at this stage.
Ann: Quarterly Activity Report - 30 June 2022, page-12
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $58.43M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $20.84K | 104.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 52724 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| NXS (ASX) Chart |